Takeda – QDENGA ® Dengue Vaccine Approved by European Commission
Returning guest, Dr. Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda discusses the dengue program and the European Commission (EC) approval of the company’s dengue vaccine, QDENGA ® (TAK-003), for the prevention of dengue disease caused by any serotype in individuals from four years of age in the European Union (EU).
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Vaccine. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Vaccine and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Vaccine?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda discusses the dengue program and the European Commission (EC) approval of the company’s dengue vac…
- Key Point: Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda.
- Key Point: In this role, he leads the global program team in the development of Takeda’s dengue vaccine, QDENGA ® (TAK-003).
- Key Point: Wallace joined Takeda in September 2013 as Global Program Medical Director.
- Key Point: Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs.
Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, he leads the global program team in the development of Takeda’s dengue vaccine, QDENGA ® (TAK-003). Dr. Wallace joined Takeda in September 2013 as Global Program Medical Director.
Dr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, he held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Dr. Wallace served as clinical team leader for Sanofi’s dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women’s health.
Dr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



